Visceral disease in castration-resistant prostate cancer

European Urology

Volumn 65, Issue 2, 2014, Pages 270-273

  Pezaro, Carmel J ^a   Omlin, Aurelius ^a   Lorente, David ^a   Nava Rodrigues, Daniel ^a   Ferraldeschi, Roberta ^a   Bianchini, Diletta ^a   Mukherji, Deborah ^a   Riisnaes, Ruth ^a   Altavilla, Amelia ^a   Crespo, Mateus ^a   Tunariu, Nina ^a   De Bono, Johann S ^a   Attard, Gerhardt ^a  

^a INSTITUTE OF CANCER RESEARCH   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ARTICLE; BONE METASTASIS; CANCER PATIENT; CASTRATION RESISTANT PROSTATE CANCER; COMPUTER ASSISTED TOMOGRAPHY; HUMAN; LIVER METASTASIS; LUNG METASTASIS; PHENOTYPE; PRIORITY JOURNAL; VISCERAL METASTASIS;

ANTINEOPLASTIC AGENTS; BONE NEOPLASMS; HUMANS; KALLIKREINS; KAPLAN-MEIER ESTIMATE; LIVER NEOPLASMS; LUNG NEOPLASMS; MALE; PHENOTYPE; PROPORTIONAL HAZARDS MODELS; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS, CASTRATION-RESISTANT; RISK FACTORS; TIME FACTORS; TOMOGRAPHY, X-RAY COMPUTED; TREATMENT OUTCOME;

EID: 84891835413     PISSN: 03022838     EISSN: 18737560     Source Type: Journal    
DOI: 10.1016/j.eururo.2013.10.055     Document Type: Article

References (10)

1. D. Pouessel, B. Gallet, and F. Bibeau et al. Liver metastases in prostate carcinoma: clinical characteristics and outcome BJU Int 99 2007 807 811
2. J.S. De Bono, S. Oudard, and M. Ozguroglu et al. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial Lancet 376 2010 1147 1154
3. H.I. Scher, K. Fizazi, and F. Saad et al. Increased survival with enzalutamide in prostate cancer after chemotherapy N Engl J Med 367 2012 1187 1197
4. Goodman OB, Flaig TW, Molina A, et al. Exploratory analysis of the visceral disease subgroup in a phase III study of abiraterone acetate in metastatic castration-resistant prostate cancer. Prostate Cancer Prostatic Dis. In press. http://dx.doi.org/10.1038/pcan.2013.41.
5. R.B. Shah, R. Mehra, and A.M. Chinnaiyan et al. Androgen-independent prostate cancer is a heterogeneous group of diseases: lessons from a rapid autopsy program Cancer Res 64 2004 9209 9216
6. C. Pezaro, and G. Attard Prostate cancer in 2011: redefining the therapeutic landscape for CRPC Nat Rev Urol 9 2012 63 64
7. A. Omlin, C. Pezaro, and D. Mukherji et al. Improved survival in a cohort of trial participants with metastatic castration-resistant prostate cancer demonstrates the need for updated prognostic nomograms Eur Urol 64 2013 300 306
8. T. Hulsen, J. de Vlieg, and W. Alkema BioVenn - a web application for the comparison and visualization of biological lists using area-proportional Venn diagrams BMC Genomics 9 2008 488
9. L. Collette Prostate-specific antigen (PSA) as a surrogate end point for survival in prostate cancer clinical trials Eur Urol 53 2008 6 9
10. J.M. Mosquera, H. Beltran, and K. Park et al. Concurrent AURKA and MYCN gene amplifications are harbingers of lethal treatment-related neuroendocrine prostate cancer Neoplasia 15 2013 1 10